The WuXi PharmaTech-backed genomic medicine developer floated below its range, after raising $125m in venture capital.
Syros Pharmaceuticals, a US-based genomic medicine developer that counts medical research contractor WuXi PharmaTech as an investor, raised $50m in its initial public offering yesterday.
The company priced four million shares at $12.50 each, below the $14 to $16 range it set last week. The IPO’s underwriters have the 30-day option to buy another 600,000 shares, which would lift the size of the offering to $57.5m.
Syros is working on drug treatments that would combat cancer and immune-mediated diseases by…
